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Abstract 
 
Evaluation of: The International Multiple Sclerosis Genetics Conssortium (IMSGC). IL12A, 
MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci. Genes. 
Immun. 11(5), 397-405 (2010). 
 
Multiple sclerosis develops in genetically susceptible populations as a result of enviromental 
exposures, and discovering these genetic and/or environmental factors will provide fundamental 
new insights into the pathogenesis, diagnosis and treatment of this disabling disease. With the 
introduction of genome-wide association studies, number of genes associated with MS has 
grown rapidly. In all of them the classic MS risk locus HLA-DRB1 stood out with remarkably 
strong statistical significance, but they also identified altogether 12 other loci and/or genes 
associated with MS. However all of these alleles have a very modest odds ratio and they explain 
∼3% of the variance in MS risk. Recently The International Multiple Sclerosis Genetics 
Consortium provided evidence for three new loci that show significant association at a genome-
wide level: RGS1, IL12A and MPHOSPH9/CDK2AP1. In this article we will review the three 
new susceptibility loci and implication of genome-wide association studies in MS on clinical 
practice. 
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MS seems unlikley to result from a single causative event; instead it seems to develop in 
genetically susceptible populations as a result of enviromental exposures. Discovering these 
genetic and/or environmental factors will provide fundamental new insights into the 
pathogenesis, diagnosis and treatment of MS. Genetics of complex disorders like MS is a 
difficult target to study. The earliest attempts consisted of a large number of studies mainly based 
on patient and control collections with small number of samples, and numerous weak 
associations were reported in the literature. Some of the identified genes have been verified by 
better-powered genetic association studies, but most have never been replicated in a follow-up . 
Things have significantly changed in the field of MS, as well as in other complex disorders with 
the introduction of genome-wide association studies. This indirect approach uses a set of 
sequence variants, single nucleotide polymorphisms (SNPs), in the genome that serve as genetic 
markers to detect association between a particular genomic region and the disease, whether or 
not the markers themselves have functional effects. (1) The main problem in the beginning was 
the reprlicability of the results. However, it became apparent that many true susceptibility genes 
in complex disorders have effect sizes so small that association significance, in order to be 
powerful enough, should have been based on significantly larger sample sets. (2) When The 
International HapMap Project determined the common patterns of DNA sequence variation in 
the human genome, it provided researchers tools that allowed the indirect association approach to 
be applied readily to the whole genome for scans of disease risk factors. (3) However it has been 
shown that most common variants individually or in combination confer relatively small 
increments in risk (1.1–1.5-fold) and explain only a small proportion of heritability. (4) The 
questions arise as to why so much of the heritability is apparently unexplained by initial genome 
wide association analysis. There are several possible explanations: a) much larger numbers of 
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variants of smaller effect are yet to be found; b) rarer variants are poorly detected by available 
genotyping arrays that focus on variants present in 5% or more of the population; c) structural 
variants are poorly captured by existing arrays; d) low power to detect gene–gene interactions; e) 
inadequate accounting for shared environment among relatives. (5) The modest size of genetic 
effects detected so far confirms the multifactorial etiology of these conditions and suggests that 
complex diseases like MS will require substantially greater research effort to detect additional 
genetic influences. (5) 
Familial aggregation is one of cardinal epidemiological features of multiple sclerosis suggesting 
that factors influencing disease onset and disease course may be in part inherited. (6) This is 
supported by twin studies (7), candidate gene population association (8) and linkage studies. (9) 
In an effort to decipher the genetic component of MS pathogenesis many candidate genes have 
been investigated, but, to date, the only region of the genome that has clearly and consistently 
shown evidence of association with the disease is the major histocompatibility complex (MHC) 
on chromosome 6p21, where, in Northern Europeans, association with the DR15 human 
leukocyte antigen (HLA) haplotype (DRB1*1501-DQB1*0602) is a constant finding. (10) It is 
believed that in addition to the HLA region, 20–100 common genetic variants might be sufficient 
to account for the genetic risk in MS. 
There are several published genome wide association studies in MS to date and in all of them the 
classic MS risk locus HLA-DRB1 stood out with remarkably strong statistical significance. 
(11,12,13) The International Multiple Sclerosis Genetics Consortium undertook a large-scale 
genome-wide association
 
scan aimed at identifying alleles associated with MS. Beside the 
already known HLA locus, the authors identified alleles of IL2RA and IL7RA as heritable risk 
factors for MS. (11) Following this, several more loci were identified and replicated in 
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independent cohorts or through meta-analysis studies. (14,15) Genome-wide association studies 
identified altogether 12 loci and/or genes associated with MS to date, however all of these alleles 
have a very modest odds ratio (16) and they explain ∼3% of the variance in MS risk. (17) These 
results statistically demonstrate a polygenic component to MS susceptibility and suggest that the 
risk alleles identified to date represent just the tip of an iceberg of risk variants likely to include 
hundreds of modest effects and possibly thousands of very small effects. 
 
Summary of methods and results 
Recently, De Jager and colleagues reported the results of a meta-analysis of genome-wide 
association studies that included 2624 MS subjects and 7220 control subjects. (15) The 
replication phase of this study was performed in an independent set of 2214 MS subjects and 
2116 controls, and the combined analysis led to the validation of three new loci that met 
genome-wide significance. Furthermore, this analysis highlighted seven loci with suggestive 
evidence of association to MS: CXCR4 (rs882300, combined P value 1.37x10
-7
), IL12A 
(rs4680534, P value 5.58x10
-6
), MPHOSPH9/CDK2AP1 (rs1790100,P value 7.21x10
-7
), 
OLIG3/TNFAIP3 (rs9321619, P value 1.71x10
-5
), PTGER4 (rs6896969, P value 2.40x10
-7
), 
RGS1(rs2760524, P value 9.77x10
-6
) and ZMIZ1 (rs1250540, P value 1.59x10
-6
). Based on this 
paper, the International Multiple Sclerosis Genetics Consortium attempted to validate these 
seven putative MS susceptibility loci by genotyping the implicated polymorphisms in new 
samples and then combining the results with those of the published meta-analysis and its 
replication effort. (18) 
This study involved 8085 MS patients and 7777 healthy controls from USA, UK, Germany, 
Italy, Sweden and Finland, and all patients were of self reported European ancestry. SNP 
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genotyping was performed at each center using different platforms (Sequenom iPLEX Gold or 
TaqMan (7900 Sequence Detection System)). One of the drawbacks of the study was that not all 
of the SNPs were successfully genotyped in each sample collection, however authors took into 
account the differences in the number of cases and controls across the polymorphisms when they 
analyzed the data. This may also explain why some of the studied loci did not reach statistically 
significant association. The results of this meta-analysis of the replication samples exhibited 
following odds ratios for seven investigated loci: RGS1 0.87 (0.81–0.92), IL12A 1.11 (1.05–
1.16), MPHOSPH9/CDK2AP1 1.10 (1.04–1.16), ZMIZ1 1.05 (0.99–1.11), OLIG3/TNFAIP3 
0.94 (0.90–0.99), PTGER4 0.94 (0.88–1.00) and CXCR4 0.91 (0.87–0.96) showing evidence of 
association at a genome-wide level of significance (P value < 5x10
-8
) in three loci: RGS1 
(rs2760524, joint P value 3.55x10-9), IL12A (rs4680534, joint P value 3.08x10-8) and 
MPHOSPH9/CDK2AP1 (rs1790100, joint P value 3.96x10-8). 
The second part of the study explored the possible functional consequences of the seven 
polymorphisms by performing a quantitative trait analysis that correlates genotyping data with 
gene expression data. Only one of the seven SNPs, rs1790100 in the MPHOSPH9/CDK2AP1 
locus, showed evidence of association in ‘cis’: the risk associated allele correlates with lower 
CDK2AP1 RNA expression in the samples from the HapMap phase II study. (19) Given this 
result, authors analyzed CDK2AP1 gene expression in another publicly available data set, the 
‘mRNAby-SNP-browser’.(20) In this data set, two of the SNPs associated with the level of 
CDK2AP1 RNA expression were in strong linkage disequilibrium with rs1790100. Authors 
further explored these in vitro observations using ex vivo RNA data obtained from peripheral 
blood mononuclear cells (PBMCs) in 255 relapsing–remitting MS and clinically isolated 
syndrome (CIS) subjects. As there was no difference between treatment naïve patients and 
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patients treated with interfernos or glatiramer acetate, all data were pooled together, and results 
showed reduced CDK2AP1 expression in the presence of the rs1790100G susceptibility allele. 
MS subjects who are homozygous for the risk (‘G’) allele have a substantial reduction of the 
CDK2AP1 expression profile compared with the other two genotype classes. 
 
 
Discussion 
 
 
This study provided us with three new genes associated with MS susceptibility.  
RGS1gene encodes a member of the regulator of G-protein signaling family. This protein is 
located on the cytosolic side of the plasma membrane and contains a conserved, 120 amino acid 
motif called the RGS domain. The protein attenuates the signalling activity of G-proteins by 
binding to activated, GTP-bound G alpha subunits and acting as a GTPase activating protein 
(GAP), increasing the rate of conversion of the GTP to GDP. The major cells of RGS1 
expression are T and B lymphocytes, natural killer (NK) cells, dendritic cells, and monocytes. 
(21) Studies of RGS1 knockout mice revealed a role for RGS1 in the control of B lymphocyte 
migration induced by chemokines (22). RGS1 regulates B cell homing to lymph nodes and 
motility within the lymph node microenvironment. Another recent study reported enrichment of 
both RGS1 and RGS16 in regulatory CD4+ T cells and activated T cells compared with naïve T 
lymphocytes (23). These studies suggest that RGS1 may play a major role in the chemokine-
mediated homing of lymphocytes to secondary lymphoid organs as well as their localization 
within these spaces during the immune response. Therefore it can be speculated that that 
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alterations in RGS1 function mediated by allelic variants could impact the migratory capability 
of B cells and possibly alter their recruitment to the central nervous system. 
It is interesting to observe that genetic variants in RGS1 have recently been observed to be 
associated with CD and diabetes type 1, and therefore it is possible that the polymorphisms in the 
RGS1 locus are tagging SNPs for a common causative inflammatory disease variant that remains 
to be discovered. (24,25)  
The second gene reported is IL12A which encodes a subunit of a cytokine that acts on T and 
natural killer cells, and has a broad array of biological activities. This cytokine is required for the 
T-cell-independent induction of interferon (IFN)-gamma, and is important for the differentiation 
of both Th1 and Th2 cells. IL-12, which is produced principally by monocytes and dendritic 
cells, is one of the major mediators of immune response that is critical for the differentiation of 
Th1 cells. (26) Similarly toRGS1, IL12A has been associated with type 1 diabetes, celiac 
disease, rheumatoid arthritis and primary billiary cirrhosis, again suggesting that the autoimmune 
diseases, despite many differences, share a number of genetic risk factors. (25,27,28) However 
the study discussed in this manuscript showed that the effect of the rs4680534C allele seems to 
be different in MS and celiac disease: the risk allele for MS seems to be protective in CD and 
vice versa. 
The third polymorphism is located in intron 12 of the MPHOSPH9 gene on chromosome 
12q24.31. This region has not been previously identified as a susceptibility locus for 
inflammatory diseases, and little is known about it. However this polymorphism strongly 
correlated with the expression of the neighboring CDK2AP1 gene. The protein encoded by this 
gene is a specific CDK2-associated protein, which is thought to negatively regulate CDK2 
activity by sequestering monomeric CDK2, and targeting CDK2 for proteolysis and has the 
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regulatory role in DNA replication during S phase of the cell cycle. CDK2AP1 was initially 
identified as a cancer-related gene by using hamster oral cancer model, but in addition to its role 
as a cell cycle regulatory molecule through two important cellular partners: CDK2 and DNA 
polymerase-alpha/primase, CDK2AP1 has a role in TGF-β induced growth arrest, cisplatin 
induced genotoxicity, and cellular apoptosis. (29) The MS susceptibility allele rs1790100G is 
associated with a lower expression of CDK2AP1, suggesting that there may be a reduced 
inhibition of DNA replication and proliferation mediated by p12DOC-1 in subjects with the risk 
allele. 
 
Five-year view 
 
The question arises whether the identification of these allelic variants is clinically meaningful. 
For each patient, the identification of a single polymorphism that is common in the general 
population, but has a small effect is not clinically significant. However, because there are many 
MS susceptibility loci with common alleles, the aggregate risk could be meaningful when 
estimating the probability that an individual will develop MS. The results from whole-genome 
association studies in MS have not yet been fully implemented in a clinical setting. The only 
attempt to do this was by De Jager and colleagues who used a weighted genetic risk score 
(wGRS) that combines weighted odds ratios from 16 loci (nine of the SNPs were located in 
validated MS susceptibility loci that were reported to exceed genome-wide significance (p<5×10-
8
) in the meta-analysis or in previous publications; and seven of the SNPs were strongly 
suggestive of association with MS in the meta-analysis (p<10
-4
 in the final joint analysis) that 
have been associated with MS for prediction of a diagnosis of MS. (30) The inclusion of 16 
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susceptibility alleles into a wGRS modestly predicted MS risk, showed consistent discriminatory 
ability in independent samples, and was enhanced by the inclusion of non-genetic risk factors 
into the algorithm (smoking, EBV antibodies status). However, the wGRS didn’t seem to be 
correlated with the conversion of CIS to MS. Others are arguing that using genetic information 
from genome-wide association studies will be futile, in other words, given that none of the high-
frequency associated alleles is sufficient to cause MS or obligatory for the development of MS, 
very few people can have their probability of developing MS accurately predicted from genetic 
testing. (31) 
On the other hand genome-wide association studies have provided us with only ∼3% of the 
variance in MS risk. There are several possible approaches to address this problem. The 
aggregate role of low-frequency rare functional gene variants in MS has not been properly 
evaluated. These uncommon variants with relatively large effects might account for part of the 
unexplained heritability in MS. To establish the associations with rare variants it is necessary to 
perform direct mapping and rare variants within a sample must first be identified. Sequencing of 
candidate genes or entire genomes is the optimal way to identify rare variants. There is emerging 
interest in association studies of rare variants and it is hypothesized that rare variants are more 
likely to be functional than common variants. (32) The advancement in this field enabled the 
launch of the 1,000 Genomes Project, which will sequence at least 1,000 genomes from 10 
different ethnic backgrounds. The project’s goals include providing a detailed catalog of human 
variants to facilitate the identification of disease causing ones. (33) 
Another possible approach is genomwe-wide copy number variation (CNV) analysis. Genomic 
structural variations are important
 
source of genetic variation. (34) It has recently been 
recognized that structural genomic variants
 
are a common cause of genetic variation in humans, 
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and such
 
variants have been reported to substantially increase the risk
 
of a number of 
multifactorial diseases. (35) For example it has been shown that the overall load of CNVs is 
greater in individuals with schizophrenia than controls and that there is association
 
between 
schizophrenia and a number of specific rare CNVs (<1% population frequency). (36) This 
remains to be investigated in MS. 
 
Key issues 
• Discovering genetic and/or environmental factors will provide fundamental new insights into the 
pathogenesis, diagnosis and treatment of MS. 
• Genome-wide association studies have been successful in discovering susceptibility loci for MS 
and other inflammatory diseases. 
• Unlike HLA DRB1*1501, most of the genetic risk factors identified so far have only a slight 
effect on susceptibility to MS (with odds ratios that range from 1.1 to 1.2); however, the risk 
alleles in these loci are common in people of European ancestry, with allele frequencies of 0·1–
0·9. 
• Genome wide association studies identified altogether 12 loci and/or genes associated with MS 
which exceed genome-wide significance (p<5×10
-8
). 
• The International Multiple Sclerosis Genetics Consortium provided evidence for three new loci 
that show evidence of association at a genome-wide level of significance: RGS1 (rs2760524, 
joint P value 3.55x10-9), IL12A (rs4680534, joint P value 3.08x10-8) and 
MPHOSPH9/CDK2AP1 (rs1790100, joint P value 3.96x10
-8
). 
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• MS patients, in the presence of the rs1790100G susceptibility allele (who are homozygous for 
the risk “G” allele) have a substantial reduction of the CDK2AP1 expression profile compared 
with the other two genotype classes. 
• Genome-wide association studies have provided us with only ∼3% of the variance in MS risk. 
• Future studies which will detect low-frequency rare functional gene variants or perform genome-
wide CNV analyses will probably give us more insight into genetic basis of MS. 
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Tables  
 
Table 1. MS genes that show evidence of association at a genome-wide level of significance. 
 
IL7R 
IL2R 
CLEC16a 
CD58 
EVI5 
TYK2 
GPC5 
RGS1 
TNFRSF1A 
IRF8 
CD226 
CD40 
RGS1 
IL12A  
MPHOSPH9/CDK2AP1 
 
